 The European Medicines Agency EMA has validated and accepted Hutchmed China Limiteds NASDAQ: HCM marketing application seeking approval for surufatinib for pancreatic and extra-pancreatic non-pancreatic neuroendocrine tumors NETs. The EMAs validation confirms that the submission is sufficiently complete and ready to commence the formal review process. 